Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albiglutide + alpha-glucosidase inhibitor
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
**Albiglutide + alpha-glucosidase inhibitor** is a combination therapy for type 2 diabetes mellitus in which **albiglutide**, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is administered alongside an **alpha-glucosidase inhibitor** (AGI) such as acarbose, miglitol, or voglibose. Albiglutide acts by mimicking the incretin hormone GLP-1, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon secretion. Alpha-glucosidase inhibitors function by inhibiting enzymes (alpha-glucosidases) in the small intestine, thus slowing carbohydrate digestion and attenuating postprandial glucose spikes. The combined use targets multiple glycemic control mechanisms: fasting and especially postprandial hyperglycemia. This combination has been studied in patients inadequately controlled on oral antidiabetic monotherapy, where it has been shown to improve HbA1c and fasting plasma glucose with a favorable safety profile and minimal hypoglycemia risk[1][5][3].
- Brand names
- TanzeumEperzan
- Other names
- albiglutide plus alpha-glucosidase inhibitor
02
Targets
Beyond the preview
Go deeper on albiglutide + alpha-glucosidase inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albiglutide + alpha-glucosidase inhibitor.